Search

Your search keyword '"Dimopoulos, Meletios‐Athanasios"' showing total 1,551 results
Start Over Author "Dimopoulos, Meletios‐Athanasios"
1,551 results on '"Dimopoulos, Meletios‐Athanasios"'

2. Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity

Author

Kostopoulos, Ioannis V., Fotiou, Despina, Gavriatopoulou, Maria, Rousakis, Pantelis, Ntanasis-Stathopoulos, Ioannis, Panteli, Chrysanthi, Malandrakis, Panagiotis, Migkou, Magdalini, Angelis, Nikolaos, Kanellias, Nikolaos, Eleutherakis-Papaiakovou, Evangelos, Theodorakakou, Foteini, Krevvata, Maria, Terpos, Evangelos, Dimopoulos, Meletios-Athanasios, Tsitsilonis, Ourania, and Kastritis, Efstathios

Published
2024
Full Text
View/download PDF

3. Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin

Author

Efentakis, Panagiotis, Choustoulaki, Angeliki, Kwiatkowski, Grzegorz, Varela, Aimilia, Kostopoulos, Ioannis V., Tsekenis, George, Ntanasis-Stathopoulos, Ioannis, Georgoulis, Anastasios, Vorgias, Constantinos E., Gakiopoulou, Harikleia, Briasoulis, Alexandros, Davos, Constantinos H., Kostomitsopoulos, Nikolaos, Tsitsilonis, Ourania, Dimopoulos, Meletios Athanasios, Terpos, Evangelos, Chłopicki, Stefan, Gavriatopoulou, Maria, and Andreadou, Ioanna

Published
2024
Full Text
View/download PDF

4. Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

Author

Yong, Kwee, Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, and Moreau, Philippe

Published
2024
Full Text
View/download PDF

8. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Author

Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

9. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Author

Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

10. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma

Author

Papadimitriou, Maria-Alexandra, Soureas, Konstantinos, Papanota, Aristea-Maria, Tsiakanikas, Panagiotis, Adamopoulos, Panagiotis G., Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Gavriatopoulou, Maria, Sideris, Diamantis C., Kastritis, Efstathios, Avgeris, Margaritis, Dimopoulos, Meletios-Athanasios, Terpos, Evangelos, and Scorilas, Andreas

Published
2023
Full Text
View/download PDF

11. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Author

Dimopoulos, Meletios Athanasios, Hungria, Vania T M, Radinoff, Atanas, Delimpasi, Sosana, Mikala, Gabor, Masszi, Tamas, Li, Jian, Capra, Marcelo, Maiolino, Angelo, Pappa, Vasiliki, Chraniuk, Dominik, Osipov, Iurii, Leleu, Xavier, Low, Michael, Matsumoto, Morio, Sule, Neal, Li, Mary, McKeown, Astrid, He, Wei, Bright, Shelley, Currie, Brooke, Perera, Sue, Boyle, Julia, Roy-Ghanta, Sumita, Opalinska, Joanna, and Weisel, Katja

Published
2023
Full Text
View/download PDF

12. Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study

Author

Paschou, Stavroula A., Karalis, Vangelis, Psaltopoulou, Theodora, Charitaki, Ioanna, Sklirou, Aimilia D., Iconomidou, Vassiliki A., Vasileiou, Vasiliki, Kassi, Georgia N., Vryonidou, Andromachi, Kokkinos, Alexander, Tentolouris, Nicholas, Hatziaggelaki, Erifili, Trougakos, Ioannis P., Terpos, Evangelos, and Dimopoulos, Meletios Athanasios

Published
2023
Full Text
View/download PDF

16. Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica region

Author

Galani, Aikaterini, Markou, Athina, Dimitrakopoulos, Lampros, Kontou, Aikaterini, Kostakis, Marios, Kapes, Vasileios, Diamantopoulos, Marios A., Adamopoulos, Panagiotis G., Avgeris, Margaritis, Lianidou, Evi, Scorilas, Andreas, Paraskevis, Dimitrios, Tsiodras, Sotirios, Dimopoulos, Meletios-Athanasios, and Thomaidis, Nikolaos

Published
2023
Full Text
View/download PDF

22. An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.

Author

Kapoor, Prashant, Nathwani, Nitya, Jelinek, Tomas, Pour, Ludek, Perrot, Aurore, Dimopoulos, Meletios‐Athanasios, Huang, Shang‐Yi, Spicka, Ivan, Chhabra, Saurabh, Lichtman, Eben, Mateos, Maria‐Victoria, Kanagavel, Dheepak, Zhao, Liang, Guillemin‐Paveau, Helene, Macé, Sandrine, van de Velde, Helgi, and Richardson, Paul G.

Subjects
MULTIPLE myeloma, CELL receptors, SURVIVAL rate, CD38 antigen, DARATUMUMAB
Abstract

Objectives: Cluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi‐centre, Phase 1, single‐agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)‐modified anti‐CD38 monoclonal antibody (mAb), with enhanced affinity towards Fc‐gamma receptor on effector cells in patients with relapsed and/or refractory (RR) MM. Methods: This study comprised two parts: Part‐A (dose‐escalation involving anti‐CD38 mAb pre‐treated and naïve patients) and Part‐B (dose expansion). Primary endpoints were maximum tolerated dose and recommended Phase 2 dose (RP2D). Results: Thirty‐seven heavily pre‐treated patients were treated in Part A. Part‐B (dose‐expansion) was not studied. Seven dose‐limiting toxicities were reported at DL3, DL5, DL6, and DL7. RP2D was determined to be 5–7·5 mg/kg. Most common treatment‐emergent adverse events were infusion‐related reactions in 70·3% (26/37) patients. Grade ≥3 thrombocytopenia was reported in 48·6% (18/37). Overall response rate was 70% in anti‐CD38 mAb naïve and 4% in anti‐CD38 pre‐treated patients, with a median progression‐free survival of 7·62 (95%CI: 2·858; not calculable) months and 2·79 (95%CI: 1·150; 4·172) months and, respectively. Conclusions: The efficacy of SAR442085 was promising in anti‐CD38 mAb naïve patients but did not extend to the larger cohort of anti‐CD38 mAb pre‐treated patients. This observation, along with transient high‐grade thrombocytopenia, could potentially limit its clinical use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Author

Façon, Thierry, Dimopoulos, Meletios-Athanasios, Leleu, Xavier P., Beksac, Meral, Pour, Ludek, Hâjek, Roman, Liu, Zhuogang, Minarik, Jiri, Moreau, Philippe, Romejko-Jarosinska, Joanna, Spieka, Ivan, Vorobyev, Vladimir I., Besemer, Britta, Ishida, Tadao, Janowski, Wojciech, Kalayoglu-Besisik, Sevgi, Parmar, Gurdeep, Robak, Pawel, Zamagni, Elena, and Goldschmidt, Hartmut

Subjects
*MULTIPLE myeloma, *LENALIDOMIDE, *CLINICAL trials, *BORTEZOMIB, *PROGRESSION-free survival, *PLASMACYTOMA
Abstract

BACKGROUND Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. METHODS In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)- negative status in patients with a complete response. RESULTS A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; PcO.OOl). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P=0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P=0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. CONCLUSIONS Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.

Author

Kostopoulos, Ioannis V., Ntanasis‐Stathopoulos, Ioannis, Rousakis, Pantelis, Malandrakis, Panagiotis, Panteli, Chrysanthi, Eleutherakis‐Papaiakovou, Evangelos, Angelis, Nikolaos, Spiliopoulou, Vasiliki, Syrigou, Rodanthi‐Eleni, Bakouros, Panagiotis, Dimitrakopoulou, Georgia, Fotiou, Despina, Migkou, Magdalini, Kanellias, Nikolaos, Paschalidis, Nikolaos, Gavriatopoulou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios‐Athanasios, Tsitsilonis, Ourania E., and Terpos, Evangelos

Published
2024
Full Text
View/download PDF

25. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, and Richardson, Paul G

Published
2022
Full Text
View/download PDF

26. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions

Author

Galani, Aikaterini, Aalizadeh, Reza, Kostakis, Marios, Markou, Athina, Alygizakis, Nikiforos, Lytras, Theodore, Adamopoulos, Panagiotis G., Peccia, Jordan, Thompson, David C., Kontou, Aikaterini, Karagiannidis, Apostolos, Lianidou, Evi S., Avgeris, Margaritis, Paraskevis, Dimitrios, Tsiodras, Sotirios, Scorilas, Andreas, Vasiliou, Vasilis, Dimopoulos, Meletios-Athanasios, and Thomaidis, Nikolaos S.

Published
2022
Full Text
View/download PDF

27. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome

Author

Papadimitriou, Maria-Alexandra, Papanota, Aristea-Maria, Adamopoulos, Panagiotis G., Pilala, Katerina-Marina, Liacos, Christine-Ivy, Malandrakis, Panagiotis, Mavrianou-Koutsoukou, Nefeli, Patseas, Dimitrios, Eleutherakis-Papaiakovou, Evangelos, Gavriatopoulou, Maria, Kastritis, Efstathios, Avgeris, Margaritis, Dimopoulos, Meletios-Athanasios, Terpos, Evangelos, and Scorilas, Andreas

Published
2022
Full Text
View/download PDF

29. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Author

Bustoros, Mark, Anand, Shankara, Sklavenitis-Pistofidis, Romanos, Redd, Robert, Boyle, Eileen M., Zhitomirsky, Benny, Dunford, Andrew J., Tai, Yu-Tzu, Chavda, Selina J., Boehner, Cody, Neuse, Carl Jannes, Rahmat, Mahshid, Dutta, Ankit, Casneuf, Tineke, Verona, Raluca, Kastritis, Efstathis, Trippa, Lorenzo, Stewart, Chip, Walker, Brian A., Davies, Faith E., Dimopoulos, Meletios-Athanasios, Bergsagel, P. Leif, Yong, Kwee, Morgan, Gareth J., Aguet, François, Getz, Gad, and Ghobrial, Irene M.

Published
2022
Full Text
View/download PDF

30. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).

Author

Trudel, Suzanne, primary, Beksac, Meral, additional, Pour, Luděk, additional, Delimpasi, Sosana, additional, Quach, Hang, additional, Vorobyev, Vladimir I., additional, Cavo, Michele, additional, Suzuki, Kazuhito, additional, Robak, Pawel, additional, Morris, Kristin, additional, Phillips-Jones, Amy, additional, Zhou, Xiaoou Linnette, additional, Fulci, Giulia, additional, Sule, Neal, additional, Kremer, Brandon, additional, Opalinska, Joanna, additional, Mateos, Maria-Victoria, additional, and Dimopoulos, Meletios Athanasios, additional

Published
2024
Full Text
View/download PDF

31. The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer

Author

Andrikopoulou, Angeliki, primary, Bletsa, Garyfalia, additional, Rouvalis, Angeliki, additional, Tsakogiannis, Dimitris, additional, Kaparelou, Maria, additional, Papatheodoridi, Alkistis, additional, Haidopoulos, Dimitrios, additional, Liontos, Michalis, additional, Dimopoulos, Meletios-Athanasios, additional, and Zagouri, Flora, additional

Published
2024
Full Text
View/download PDF

32. Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity

Author

Efentakis, Panagiotis, primary, Varela, Aimilia, additional, Lamprou, Sofia, additional, Papanagnou, Eleni‐Dimitra, additional, Chatzistefanou, Michail, additional, Christodoulou, Andriana, additional, Davos, Constantinos H., additional, Gavriatopoulou, Maria, additional, Trougakos, Ioannis, additional, Dimopoulos, Meletios Athanasios, additional, Terpos, Evangelos, additional, and Andreadou, Ioanna, additional

Published
2024
Full Text
View/download PDF

34. Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country

Author

Koutsis, Georgios, Kastritis, Efstathios, Kontogeorgiou, Zoi, Kartanou, Chrisoula, Kokotis, Panagiotis, Rentzos, Michail, Breza, Marianthi, Kleopa, Kleopas A., Christodoulou, Kyproula, Oikonomou, Evangelos, Anastasakis, Aris, Angelidakis, Panagiotis, Sarmas, Ioannis, Kargiotis, Odysseas, Tzagournissakis, Minas, Zaganas, Ioannis, Foukarakis, Emmanouil, Sachpekidis, Vasileios, Papathoma, Alexandra, Panas, Marios, Stefanis, Leonidas, Dimopoulos, Meletios Athanasios, and Karadima, Georgia

Published
2021
Full Text
View/download PDF

36. COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus

Author

Paschou, Stavroula A., Karalis, Vangelis, Psaltopoulou, Theodora, Charitaki, Ioanna, Sklirou, Aimilia D., Iconomidou, Vassiliki A., Vasileiou, Vasiliki, Kassi, Georgia N., Vryonidou, Andromachi, Kokkinos, Alexander, Tentolouris, Nicholas, Hatziaggelaki, Erifili, Trougakos, Ioannis P., Terpos, Evangelos, and Dimopoulos, Meletios-Athanasios

Published
2023
Full Text
View/download PDF

38. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Author

Moreau, Philippe, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Spicka, Ivan, Baker, Ross, Kihyun, Kim, Martinez, Gracia, Chang-Ki, Min, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Youngil, Koh, Suzuki, Kenshi, Martin, Tom, Quach, Hang, Lim, Andrew, Crowther, Helen, Sia, Hanlon, Hulin, Cyrille, Mohty, Mohamad, Mikala, Gabor, Nagy, Zsolt, Reinoso Segura, Marta, Rosinol, Laura, Yagci, Munci, Turgut, Mehmet, Garg, Mamta, Parmar, Gurdeep, Augustson, Brad, Castro, Nelson, Crusoe, Edvan, Pika, Tomas, Delimpasi, Sosana, Ishizawa, Kenichi, George, Anup, Konstantinova, Tatiana, De La Rubia, Javier, Sung-Hyun, Kim, Maiolino, Angelo, Reiman, Anthony, LeBlanc, Richard, Ito, Shigeki, Tanaka, Junji, Luchinin, Alexander, Kryuchkova, Irina, Martinez, Joaquin, Shustik, Jesse, Karlin, Lionel, Symeonidis, Anargyros, Egyed, Miklos, Petrini, Mario, Cavo, Michele, Uchiyama, Michihiro, Blacklock, Hilary, Arat, Mutlu, Griffin, James, Hunter, Hannah, Buck, Tonda, Anagnostopoulos, Achilles, Konstantopoulos, Konstantinos, Masszi, Tamas, Bringhen, Sara, Gamberi, Barbara, Kawano, Yawara, Jin Seok, Kim, Ozdogu, Hakan, Ozkalemkas, Fahir, Špička, Ivan, Kim, Kihyun, Min, Chang-Ki, Koh, Youngil, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, and Martin, Thomas

Published
2021
Full Text
View/download PDF

44. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone:analyses from the phase III OCEAN study

Author

Schjesvold, Fredrik H., Ludwig, Heinz, Delimpasi, Sossana, Robak, Pawel, Coriu, Daniel, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios Athanasios, Masszi, Tamas, Chernova, Natalia G., Sandberg, Anna, Thuresson, Marcus, Norin, Stefan, Bakker, Nicolaas A., Mateos, Maria Victoria, Richardson, Paul G., Sonneveld, Pieter, Schjesvold, Fredrik H., Ludwig, Heinz, Delimpasi, Sossana, Robak, Pawel, Coriu, Daniel, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios Athanasios, Masszi, Tamas, Chernova, Natalia G., Sandberg, Anna, Thuresson, Marcus, Norin, Stefan, Bakker, Nicolaas A., Mateos, Maria Victoria, Richardson, Paul G., and Sonneveld, Pieter

Published
2024

45. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Tam, Constantine S, Opat, Stephen, D'Sa, Shirley P, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen P, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward N, Matous, Jeffrey V, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Véronique, Treon, Steven P, Trotman, Judith, Wu, Binghao, Yu, Yiling, Shen, Zhirong, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Cohen, Aileen, Dimopoulos, Meletios-Athanasios A, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Tam, Constantine S, Opat, Stephen, D'Sa, Shirley P, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen P, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward N, Matous, Jeffrey V, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Véronique, Treon, Steven P, Trotman, Judith, Wu, Binghao, Yu, Yiling, Shen, Zhirong, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Cohen, Aileen, and Dimopoulos, Meletios-Athanasios A

Published
2024

47. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Author

Dimopoulos, Meletios Athanasios, Beksac, Meral, Pour, Ludek, Delimpasi, Sosana, Vorobyev, Vladimir, Hang Quach, Spicka, Ivan, Radocha, Jakub, Robak, Pawel, Kihyun Kim, Cavo, Michele, Kazuhito Suzuki, Morris, Kristin, Pompilus, Farrah, Phillips-Jones, Amy, Zhou, Xiaoou L., Fulci, Giulia, Sule, Neal, Kremer, Brandon E., and Opalinska, Joanna

Subjects
*MULTIPLE myeloma, *TERMINATION of treatment, *PROGRESSION-free survival, *DEXAMETHASONE, *OVERALL survival
Abstract

BACKGROUND Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse. Frontline lenalidomide therapy has increased the number of patients with lenalidomide-refractory disease at the time of the first relapse. METHODS In this phase 3, randomized, open-label trial, we evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd), as compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients who had relapsed or refractory myeloma after at least one line of therapy. The primary end point was progression-free survival. Disease response and safety were also assessed. RESULTS A total of 302 patients underwent randomization; 155 were assigned to the BPd group, and 147 to the PVd group. At a median follow-up of 21.8 months (range, <0.1 to 39.2), the 12-month estimated progression-free survival with BPd was 71% (95% confidence interval [CI], 63 to 78), as compared with 51% (95% CI, 42 to 60) with PVd (hazard ratio for disease progression or death, 0.52; 95% CI, 0.37 to 0.73; P<0.001). Data on overall survival were immature. The percentage of patients with a response to treatment (partial response or better) was 77% (95% CI, 70 to 84) in the BPd group and 72% (95% CI, 64 to 79) in the PVd group; 40% (95% CI, 32 to 48) and 16% (95% CI, 11 to 23), respectively, had a complete response or better. Grade 3 or higher adverse events occurred in 94% of the patients in the BPd group and 76% of those in the PVd group. Ocular events occurred in 89% of the patients who received BPd (grade 3 or 4 in 43%) and 30% of those who received PVd (grade 3 or 4 in 2%); ocular events in the BPd group were managed with belantamab mafodotin dose modification. Ocular events led to treatment discontinuation in 9% of the patients in the BPd group and in no patients in the PVd group. CONCLUSIONS Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDR Acinetobacter baumannii and Literature Review.

Author

Tatouli, Ioanna, Dedes, Nikolaos, Bozikas, Andreas, Melliou, Stamatoula, Pavlou, Maria-Markella, Kontogiannis, Sofoklis, Kyrodimos, Efthymios, Kanioura, Eftychia, Ntanasis-Stathopoulos, Ioannis, Dimopoulos, Meletios-Athanasios, Dimopoulos, George, Kastritis, Efstathios, and Gavriatopoulou, Maria

Subjects
BLOOD diseases, LITERATURE reviews, HEMOPHAGOCYTIC lymphohistiocytosis, ACINETOBACTER baumannii, MULTIPLE myeloma
Abstract

Immunocompromised patients with hematologic diseases may experience life-threatening infections with rather uncommon manifestations. Laryngitis has been described as a potential infection in such vulnerable patients and may result in major complications, ranging from impending airway obstruction to total laryngeal necrosis. Immediate laryngoscopy is of paramount importance, as it provides quantification of laryngeal edema and evidence of necrosis. Documentation of the causative pathogen is usually feasible through tissue culture. In the literature, 14 cases of necrotizing laryngitis have already been published. Here, we present the case of a 38-year-old male with a recent diagnosis of multiple myeloma, who received the first cycle of therapy a few days before admission. The patient presented with neutropenic fever, diarrhea, and multiple organ dysfunction. His course was complicated with hemophagocytic lymphohistiocytosis and stridor. A diagnosis of necrotizing laryngitis attributed to Acinetobacter baumannii invasion of the larynx was established. This manuscript highlights that the management of patients with hematologic disease and necrotizing laryngitis should be coordinated in highly specialized centers and clinicians should have a high level of clinical suspicion and act promptly. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results